

1 Title: Prevalence of Fetal Alcohol Spectrum Disorder (FASD) in Greater Manchester, UK: an
2 active case ascertainment study

3

4 Robyn McCarthy MSc¹, Raja A.S. Mukherjee PhD^{1,2}, Kate M. Fleming PhD³, Jonathan Green
5 FRCPsych⁴, Jill Clayton-Smith MD⁵, Alan D. Price PhD¹, Clare S. Allely PhD¹, Penny A. Cook
6 PhD*¹

7 ***Correspondence to:** Penny A. Cook

8 School of Health and Society,

9 University of Salford,

10 Allerton Building

11 Frederick Road

12 Salford M6 6PU

13 p.a.cook@salford.ac.uk

14 Tel: +44(0)161 295 2804

15

16

17 1. School of Health and Society, University of Salford , UK

18 2. Fetal Alcohol Spectrum Disorder Service, Surrey & Borders NHS Trust, UK School of

19 Health and Society, University of Salford, UK

20 3. Institute of Population Health Sciences, University of Liverpool, UK Division of

21 4.Neuroscience & Experimental Psychology, University of Manchester, UK Royal Manchester

22 Children's Hospital, Manchester, UK

23 5.Royal Manchester Children's Hospital, Manchester, UK Division of Evolution & Genomic

24 Sciences, University of Manchester, UK

25 Funding

26 This project was funded by The Greater Manchester Health and Social Care Partnership. The
27 funders had no role in study design, data collection and analysis, decision to publish, or the
28 preparation of the manuscript.

29 Conflicts of interest

30 RASM has received honoraria from speaking for various pharmaceutical companies related
31 to ADHD including Takeda, Flynn and Janssen, as well as support for entry to an
32 international conference related to ADHD. RASM is also a non-paid advisor to various ASD,
33 ADHD and FASD charities in England and Internationally (Australia and Europe). RASM has
34 organised conferences and obtained non educational grants from various sources including
35 Pharma and private hospitals. AP is an non-paid member of the Professional Advisory Panel
36 of the not-for-profit organisation, ÉNDpae. All other authors declare that they have no
37 competing interests.

38 Acknowledgments

39 We thank the parents, guardians, children, head teachers and staff at participant schools.
40 We also thank Róisín Reynolds and Rachael Nielsen from the Greater Manchester Health
41 and Social Care Partnership for their support. Philip May allowed us to use the Maternal Risk
42 Questionnaire, the University of New Mexico by the Fetal Alcohol Syndrome Epidemiology
43 Research Team initially developed in collaboration with Sharon Wilsnack (University of
44 North Dakota), and adapted and updated multiple times for use in prevalence studies in the
45 United States, South Africa, and Italy. We thank those who represented families affected by

46 FASD, led by Anna Webster. We thank the members of an independent steering group,
47 including Anna Webster Jen Michaels, Joanne Higham, Mary Scanlon and Susan McGrail.

48

49 Abstract

50 **Background:** Despite high levels of prenatal alcohol exposure in the UK, evidence on the
51 prevalence of fetal alcohol spectrum disorders (FASD) is lacking. This paper reports on FASD
52 prevalence in a small sample of children in primary school.

53 **Methods:** A two-phase active case ascertainment study was conducted in three
54 mainstream primary schools in Greater Manchester, UK. Schools were located in areas that
55 ranged from relatively deprived to relatively affluent. Initial screening of children aged 8-9
56 years used pre-specified criteria for elevated FASD risk (small for age; special educational
57 needs; currently/previously in care; significant social/emotional/mental health symptoms).
58 Screen positive children were invited for detailed ascertainment of FASD using gold
59 standard measures including medical history, facial dysmorphology, neurological
60 impairment, executive function and behavioural difficulties.

61 **Results:** Of 220 eligible children, 50 (23%) screened positive and 12% (26/220) proceeded to
62 phase-two assessment. Twenty had a developmental disorder, of which, four had FASD and
63 four were assessed as possible FASD. The crude prevalence rate of FASD in these schools
64 was 1.8% (95%CI: 1.0%,3.4%) and when including possible cases was 3.6% (2.1%,6.3%).
65 None of these children had previously identified with a developmental diagnosis.

66 **Conclusions:** FASD was found to be common in these schools, but limitations to the
67 sampling restrict inferences to a population prevalence. Most of these children's needs had
68 not previously been identified.

69

70 Keywords (5)

71 FASD; Fetal Alcohol Syndrome (FAS); neurodevelopmental disorder; attention deficit

72 hyperactivity disorder (ADHD); Autism Spectrum Disorder (ASD)

73

74 Introduction

75 An estimated 10% of pregnancies globally are exposed to alcohol, a potent teratogen that
 76 can lead to physical and neurodevelopmental birth defects (Popova et al., 2017), collectively
 77 known as Fetal Alcohol Spectrum Disorders (FASD) (Cook et al., 2016). FASD is an umbrella
 78 term that includes the diagnoses of Fetal Alcohol Syndrome (FAS), pFAS (partial Fetal
 79 Alcohol Syndrome), ARBD (Alcohol-Related Birth Defects), and ARND (Alcohol-Related
 80 Neurodevelopmental Disorder)/ND-PAE (Neurobehavioral Disorder Associated with Prenatal
 81 Alcohol Exposure).

82 The prevalence of FASD is estimated to be 0.8% globally and highest in Europe, at 2% (Lange
 83 et al., 2017a). There are no direct estimates of prevalence in the four countries with the
 84 highest known rates of prenatal alcohol exposure (Ireland, Belarus, Denmark and UK), all of
 85 which have rates of over 40% pregnancies exposed to alcohol (Popova et al., 2017). For the
 86 UK, the modelled estimate suggests 3.2% of children and young people may have FASD
 87 (Lange et al., 2017a). A national study in the US, on populations relatively similar to those in
 88 the UK, found a weighted estimate of 3-10% for FASD in children in primary school (May et
 89 al., 2018). Where a UK cohort with high levels of exposure (79% of mothers drank during the
 90 pregnancy, with 25% at binge levels) was used, 6–17% of children screened positive for
 91 features of FASD (McQuire et al., 2019). However, the lack of direct evidence of prevalence
 92 contributes to under-investment in diagnostic, treatment and prevention services (Scholin
 93 et al., 2021).

94 Active case ascertainment studies, the basis of global and national prevalence estimates
 95 (Lange et al., 2017a; May et al., 2018), are considered the ‘gold standard’ method of
 96 estimating prevalence, and involve screening a cross section of the general population of

children (Roozen et al., 2016). Passive methods are less useful because individuals with FASD are often not diagnosed (May & Gossage, 2001; Morleo et al., 2011) for a number of reasons, including a lack of knowledge/training among healthcare/educational professionals (Mukherjee et al., 2015); difficulty in differentiating features of FASD from other commonly co-occurring disorders (e.g. Attention-Deficit/Hyperactivity Disorder, ADHD, or Autism Spectrum Disorder, ASD) (Chasnoff, Wells & King, 2015; Mukherjee et al., 2011; Young et al., 2016).

The aim of this study was to provide direct evidence of the prevalence of FASD in a small sample of UK children aged 8 to 9 years.

Materials and Methods

Setting

The setting was Greater Manchester, North West England (population 2.8 million), an area with a higher than England average level of alcohol harm (Public Health England, 2021), and relatively high deprivation (Ministry of Housing Communities and Local Government, 2019).

This study was part of a wider initiative, the ‘Preventing Alcohol Exposed Pregnancy Programme’ taking place in four of the ten Greater Manchester local authority areas. The initiative also included increased awareness raising and interventions with women who were pregnant or at risk of unplanned pregnancy (Reynolds et al., 2021).

Design

We report on a cross-sectional study to detect cognitive impairments and associated conditions, including FASD, using an Active Case Ascertainment method. Based on the World Health Organization (WHO) standard protocol for FASD prevalence studies (World Health

Organisation, 2012), children in school year three/four (8-9 years of age at enrolment) who were able to communicate in English were invited to take part in a two-phase approach. Children with a known risk factor for FASD went to the second phase 'Children with a known risk factor for FASD went to the second phase (full assessment, see section below, phase 1: initial screening, Figure 1). Child assessments took place between July 2019 and March 2020. Restrictions related to the COVID-19 pandemic prevented face to face data collection from mid-March 2020, at which point there was one outstanding parent interview, which was conducted by telephone in March 2020.

Sample size

A sample size of 170 was adequate to get a preliminary indication of prevalence in a selected sample of schools (based on estimated true prevalence=0.03, precision=0.05; sensitivity=0.85; specificity=0.85). We aimed to recruit three schools (assuming approximately 60 pupils in the relevant age category per school).

School recruitment

In this pragmatic, small-scale study, schools were purposefully selected. Key informants (e.g. local government officials who work with schools, Education Psychologists) were consulted and suggested four schools, all of which agreed to take part. One school was excluded due to disengagement from the study and deviation from the protocol (see supplementary file 1 for details of a partial dataset). We initially aimed to include a specialist school providing Social Emotional and Mental Health (SEMH) support. All such schools within the study area were contacted. One such school agreed to take part but withdrew after being unable to gain consent from any parents.

In February 2020, an extension of data collection was granted with the aim to recruit further schools to increase the baseline sample size. Four additional schools were recruited. However, the imposition of COVID-19 related restrictions, including lockdown, meant that the study could not be completed in the second wave of schools. Partial results are reported in Supplementary file 1.

Phase 1: Initial Screening

Parents of all eligible children were sent a letter describing the study, with the option to opt out, at least five days before data collection. Parents who wished to remove their child from the study at this stage were advised to return the letter with the opt-out option selected. Researchers were present in school to assess physical measurements. Height was measured using a mobile stadiometer, weight using Marsden MBF-6000 scales and head circumference (OFC) using a Sec 201 measuring tape. To become eligible for phase 2 (full assessment), one or more of the following criteria had to be met: height or weight below the ninth centile or OFC below the second centile; identified by the school or parents as having difficulties with learning, maladaptive behaviour, inattention or hyperactivity issues; have an Education Health and Care plan; be a currently or previously looked after child; already have diagnosed difficulties with behaviour including ADHD or conduct disorder. Exclusion criteria: disabilities or behavioural abnormalities known to be caused by well-characterised and already identified genetic factors (e.g. Down Syndrome, Williams Syndrome) or by post-natal brain injuries. These were excluded because the physical/behavioural stigmata overlap with FASD in presentation, and an FASD label cannot be attributed as the primary aetiological factor.

Phase 2a: Measures completed by parents/carers

Parents of those meeting criteria for phase 2 were sent information sheets and consent forms to opt themselves and their child into the study either by email, letter sent home, by telephone or in person by the Special Educational Needs Coordinator or head teacher. Where children were currently under the care of the local authority consent was obtained from the supervising social worker. For parent-report assessments, most took place at school in a private room for two-hour sessions. Where requested by the parent, assessments took place in their home.

Parent report assessments used the validated measures listed in Figure 1. The medical history was taken using a structured questionnaire developed originally at the University of New Mexico (May et al., 2018). The schedule included questions on pre-pregnancy, pregnancy and current substance use (alcohol, tobacco, prescription and illicit drugs), folic acid use in pregnancy and birth complications. General questions on current alcohol consumption were asked first as part of wider lifestyle set of questions, followed by questions about alcohol consumption in pregnancy. If alcohol was consumed during pregnancy, further questions ascertained the level and timing of consumption. Birth mothers were interviewed privately in order to encourage open reporting of alcohol use. For looked after children, fostered or adopted children, the parent/carer with most knowledge of the child was interviewed.

Phase 2b: Measurements on children

Measurements took place in school during school hours. Dysmorphology of fetal alcohol syndrome (FAS) facial characteristics was assessed from photographs (using standardised alignment of the participant's head relative to the camera lens) taken by trained

researchers. Images were analysed by FAS Facial Photographic Analysis Software (Astley, 2015) and validated by an experienced clinical geneticist. Neurological impairment was assessed using the Developmental NEuroPSYchological Assessment (NEPSY) to assess memory, attention, and executive functions. The NEPSY subtests (Inhibition, Narrative Memory and Word List Interference, Animal Sorting, Clocks and Memory for Faces) were those that had been identified in previous FASD research (Rasmussen et al., 2013). The Wechsler Intelligence Scale for Children (WISC V) (Kaufman et al., 2015) was used to assess the child's cognition, as used in previous FASD studies (Raldiris et al., 2018).

Phase 2c: Ruling out genetic causes and case conference

The results of the assessments were compared to the case definition (Table 1), derived from the WHO protocol for prevalence studies (World Health Organisation, 2012) and international guidelines (Cook et al., 2016). Where deficits met criteria in three subdomains, and PAE was present, FASD was considered. Where a child had all three sentinel facial features associated with FAS, FASD was considered in the absence of reported PAE. For all those considered for FASD, a Microarray Comparative Genomic Hybridisation (array CGH) test was used to rule out other disorders that may present with a similar behavioural presentation of genetic origin (Douzgou et al., 2012). A saliva sample was taken using the Oragene DNA OG-575 (DNAGenotek, 2020). The Oligo (Oxford Gene Technology, Oxford, UK) Hx60k array was carried out by the North Western Regional Genetics Laboratory within Manchester University NHS Foundation Trust, Manchester.

Findings for each child discussed during case conferences attended by the study team including clinicians with expertise in the diagnosis of FASD. Cases of FASD were defined according to internationally recognised guidelines (Cook et al., 2016). Possible cases were

210 where FASD was suspected but information was missing or unclear, for example regarding
211 alcohol use.

212 Data analysis

213 Prevalence was estimated as the total number of children with FASD and probable FASD as
214 the numerator, and the total number of eligible children at the same site as the
215 denominator. This generates a conservative or minimum estimate of prevalence as it
216 assumed that all children who were not examined did not have FASD. To obtain confidence
217 intervals we accounted for clusters (schools) by using nonparametric bootstrapping,
218 resampling with replacement clusters with 10000 bootstrap runs.

219 Ethical considerations

220 Parents were invited to take part and were offered a report on their child's learning and
221 behaviour issues, which could include a range of learning difficulties, including possible ASD,
222 ADHD and FASD. The text of the information sheet made it clear that the main objective was
223 to ascertain FASD prevalence.

224 A small number of participants took part in genetic testing, which can occasionally identify
225 markers for other health conditions. The information sheet sought to ensure that the
226 parents/carers understood possible outcomes of the genetic test before giving consent.

227 Ethical approval was granted by the University of Salford Ethics committee in May 2019
228 (reference: HSR1819-100).

Results

Participating schools

Schools represented a range of deprivation when measured by the index of multiple deprivation. School 1 was located in one of England's 20% most deprived areas, and school 3, 30%. School 2 was located among the 20% most affluent areas in England.

Flow of participants

A total of 220 children were invited and 203 children took part in the phase 1 physical measures (height, weight and OFC) (Figure 2). Fifty children were eligible for full assessment (phase 2) because of screening positive on the physical measures, parent/teacher concerns, already acknowledged as SEN, or currently or previously being in local authority care (Table 2).

Assessment was not possible on 24 children due largely to parents not giving consent or being uncontactable.

Full assessment took place with 26 children, four of whom had FASD and a further four were identified as possible FASD (Table 2). Other developmental disorders identified are detailed in supplementary file 2.

Of the children with full data sets, none had reported exposure to known teratogenic antiepileptic pharmaceuticals. Two had exposure to illegal drugs and over two thirds of the children assessed (68%) has some prenatal exposure to alcohol (Table 3).

Of the FASD cases, none had a prior clinical diagnosis of any neurodevelopmental disorder or an Education, Health and Care (EHC) Plan, and only one child had been identified by the school as having special educational needs. Three out of the four cases had high risk

prenatal alcohol exposure reported, while in the fourth, alcohol was not reported but the child had severe FAS facial features, was small for age, a low full scale IQ of 66, and a normal CGH array (a summary of cases and possible cases assessed against the FASD criteria is given in supplementary file 2).

Of the possible cases where FASD was suspected but not confirmed, none had a clinical diagnosis of any neurodevelopmental disorder and only one had an EHC Plan. All were on the schools' special educational needs register, had prenatal exposure to alcohol, and had deficits in at least three subdomains. Of the 12 children with a suspected disorder that was deemed unlikely to be FASD, 11 had some level of prenatal exposure to alcohol (Table 3).

Prevalence Rates

We calculated a conservative (minimum) prevalence of FASD of 1.8% 4/220 (95% CI [1.0, 3.4]), and a conservative (minimum) prevalence that also included possible FASD of 3.6% 8/220 (95%CI [2.1, 6.3]) within our study population.

Discussion

Prevalence of FASD

This is the first FASD active case ascertainment study to be carried out in the UK, a country with one of the highest rates of drinking in pregnancy in the world. These prevalence estimates, though not necessarily generalisable to other communities, are in line with a modelled population prevalence estimate for the UK of 3.2% (Lange et al., 2017b) and consistent with a screening prevalence of 6-17% in a secondary analysis of data from a cohort study of children born in the 1990s (McQuire et al., 2019). As per May et al. (2018),

our prevalence estimates could be considered as ‘conservative’ because we assumed all those who we did not fully assess did not have FASD. Further work examining the prevalence of FASD taking account of maternal sociodemographic factors and trends in alcohol consumption would allow a more precise estimate of the likely burden of this condition in the UK.

The study region (Greater Manchester) sees approximately 34,000 babies born per year (ONS, 2020), yet diagnoses only around 36 cases of FASD per year (unpublished data from a Freedom of Information request). This low rate of diagnosis in relation to the example local prevalence we have demonstrated here suggests that increased recognition and diagnostic capacity is required. This is important because early diagnosis and support for families affected by FASD can prevent or mitigate adverse secondary outcomes, such as school exclusions, poor job prospects and mental ill-health (Alex & Feldmann, 2012; Landgren, et al., 2019; Rangmar, et al., 2016; Streissguth, et al., 2004).

Strengths and Limitations

We demonstrated successful engagement with the three schools who made intensive efforts on our behalf to recruit parents. The schools covered a range of communities in different levels of deprivation, with two serving relatively deprived populations and one relatively affluent. A larger, more definitive study would use a random sampling technique, stratified by deprivation level, to select schools.

We were unable to obtain sufficient information for almost half (24/50) of the children who were identified as being at higher risk of FASD (i.e. those who were identified in phase 1 screening). A further nine were actively withdrawn before phase 1 screening and selection took place. It is not possible to know whether the proportion of cases would have been

higher or lower in these groups that did not take part. It is also possible that there were cases of FASD in the remaining 161 children with no apparent risk factors. It is possible the shame and stigma associated with FASD or developmental disorders in general may have impacted on participation. Low participation has been a documented issue for other prevalence studies (Caccanti et al., 2014; May et al., 2011; Okuliez-Kozaryn, et al., 2017) in the European region.

Extensive effort was made to contact each parent, and for those not taking part, the reasons were documented (see reasons given in Figure 2). The opportunity to have children's needs assessed was the major incentive for schools to take part in the study. For children in the care of foster parents, consent was required from the local authority and this was particularly difficult to obtain.

We had initially hoped to include a further four schools in the prevalence calculations, however, disruptions due to COVID-19 prevented completion in these schools. Partial findings are presented in supplementary file 1.

We were not successful in collecting data in a Social Emotional and Mental Health (SEMH) school despite recruiting an enthusiastic head teacher at such a school. Anecdotally, parents felt they had nothing to gain by taking part as their child was already benefiting from specialist support. Similarly, pupil referral units were not included in this study. Together with SEMH schools, this is another setting where FASD prevalence is anticipated to be higher than the mainstream school setting.

It is likely that prenatal alcohol exposure was underestimated in this study, as dose and duration of alcohol consumption during pregnancy was calculated from retrospective self-reporting, relying on recall of behaviours taking place up to 10 years prior. Social desirability

bias also affects reporting of alcohol consumption during pregnancy (Caccanti et al., 2014, Smith et al., 2014) and we do not know how much the potential for perceived shame associated with alcohol consumption in pregnancy may have affected reporting.

It may be beneficial for future research to consider how methods could be adjusted for European populations to optimise participation and accuracy of report of alcohol consumption in these populations.

Other general limitation in studies that measure the prevalence of FASD, it that whilst there are a wide range of physical and neurological features associated with FASD, which when taken together increase the likelihood of FASD, the only features that are widely accepted as discriminating in the absence of confirmed alcohol exposure are the distinctive facial features. However, significant facial features are thought to only occur in a minority of cases of FASD, and, likewise, in this study only two out of the eight cases and possible cases showed these distinctive features. Previous prevalence studies have used a higher threshold for the physical measurements at phase 1 (e.g. a threshold of 10th percentile for OFC: May et al., 2011), which would have made the screening stage more sensitive and may have led to more cases being identified. Instead, we used the Canadian diagnostic approach, where the detailed evaluation stage was more focused towards the neurocognitive deficits. We ruled out obvious genetic causes through chromosome microarray analysis and clinical geneticist review. Whilst this helped to improve confidence about the aetiological basis of the presentation, it is not possible to prove that the alcohol exposure caused the deficits. The converse also true: it is not possible to rule out alcohol as an important causal factor. Every effort was taken to reduce bias that may give rise to false positives. The case

definition used validated developmental assessments and was described in advance in the study protocol and followed internationally recognised guidance (Cook et al., 2016).

An improvement on our methodology would have been to include a random sample of children for full assessment. This would have enabled us to obtain characteristics of the birth mothers in a group of children without any risk factors for FASD (i.e. those who did not meet the phase 1 screening criteria), which would have allowed more sophisticated modelling (and extrapolation) of the likely prevalence in the entire population of 8-9 year olds (May et al., 2018). In this small-scale study, we determined that this would have been difficult. Parents were prepared to take part if they thought it might benefit their child, for example by getting more information to inform their special educational needs or to obtain a diagnosis. The fact that our assessment also identified possible ASD, ADHD and other neurodevelopmental conditions was a significant ‘pull factor’ for schools and parents. It was also notable that the only children actively opted into the study because of parent concerns (and no other risk factor) were from the school in the most affluent setting (school 2). Thus, motivations to take part may differ depending on socioeconomic status. We would conclude that further research would be needed into how to incentivise parents of children with apparently typical development to take part.

Conclusions

This is the first study in the UK to directly assess FASD in a systematically ascertained sample of children. It found FASD in 1.8% (1.0%-3.4%) of the population studied, or 3.6% (2.1%,6.3%) when possible cases were also included. Due to the small sampling frame of schools included and limitations of baseline information obtained on contacted families, we can only conclude this represents local prevalence data in typical mainstream schools rather

364 than being able confidently to infer a 'population prevalence' of FASD. There are
 365 uncertainties too about this prevalence found, since half the children screened positive
 366 were lost to full ascertainment, and case identification may have been higher if all cases had
 367 been seen. Further research is needed to identify how to improve participation and
 368 accuracy of PAE in European populations.

369 It was already suspected from modelling and screening studies that FASD is highly prevalent
 370 in the UK (Lange et al., 2017a; McQuire et al., 2019). Confirmation that this is the case in a
 371 sample of schools should be used to increase the awareness of FASD, and invest in
 372 diagnostic services, treatment and support for those affected by FASD.

373 Abbreviations

ADHD	Attention-Deficit/Hyperactivity Disorder
ARBD	Alcohol-Related Birth Defects
ARND	Alcohol-Related Neurodevelopmental Disorder)/
ASD	Autism Spectrum Disorder
CCC	Children's communication Checklist
FAS	Fetal Alcohol Syndrome
FASD	Fetal Alcohol Spectrum disorders
FSIQ	Full Scale Intelligence Quotient
IDACI	Income Deprivation Affecting Children Index
IMD	Index of Multiple Deprivation
ND-PAE	Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure
NEPSY II	NEuroPSYchological Assessment 2 nd Edition
NHS	National Health Service
OFC	Occipital Frontal Circumference
PAE	Prenatal Alcohol Exposure
pFAS	partial Fetal Alcohol Syndrome
SCQ	Social Communication Questionnaire
SDQ	Strengths and Difficulties Questionnaire
SEMH	Social, Emotional And Mental Health School
SEN	Special Educational Needs
SENCO	Special Educational Needs Coordinator
SFA	Small for age
SSP	Short sensory profile
WISC V	Weschler Intelligence scale for Children 5 th Edition

374

375

376

References

- Alex, K. & Feldmann, R. 2012. Children and adolescents with fetal alcohol syndrome (FAS): better social and emotional integration after early diagnosis. *Klin Padiatr*, 224, 66-71.
- Astley, S. J. 2015. Palpebral fissure length measurement: accuracy of the FAS Facial Photographic Analysis Software and inaccuracy of the ruler. *Journal of Population Therapeutics and Clinical Pharmacology*, 22(1).
- Ceccanti, M., Fiorentino, D., Coriale, G., Kalberg, W. O., Buckley, D., Hoyme, H. E., ... & May, P. A. (2014). Maternal risk factors for fetal alcohol spectrum disorders in a province in Italy. *Drug and Alcohol Dependence*, 145, 201-208.
- Chasnoff, I J., Wells, A.M., King, L. 2015. "Misdiagnosis and missed diagnoses in foster and adopted children with prenatal alcohol exposure." *Pediatrics* 135.2, 264-270.
- Cook, J. L., Green, C. R., Lilley, C. M., Anderson, S. M., Baldwin, M. E., Chudley, A. E., Conry, J. L., Leblanc, N., Loock, C. A., Lutke, J., Mallon, B. F., Mcfarlane, A. A., Temple, V. K. & Rosales, T. 2016. Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. *Can. Med. Assoc. J.*, 188, 191-197.
- Dnagenotek 2020. Oragene 500-series. *Genotek*.
- Douzgou, S., Breen, C., Crow, Y. J., Chandler, K., Metcalfe, K., Jones, E., Kerr, B. & Clayton-Smith, J. 2012. Diagnosing fetal alcohol syndrome: new insights from newer genetic technologies. *Arch. Dis. Child.*, 97, 812-817.
- Kaufman, A. S., Raiford, S. E. & Coalson, D. L. 2015. *Intelligent testing with the WISC-V, USA*, John Wiley & Sons.

399 Kelly, Y., Sacker, A., Gray, R., Kelly, J., Wolke, D., & Quigley, M. A. (2009). Light drinking in
400 pregnancy, a risk for behavioural problems and cognitive deficits at 3 years of age?
401 International journal of epidemiology, 38(1), 129-140.

402 Landgren, V., Svensson, L., Gyllencreutz, E., Aring, E., Grönlund, M. A., & Landgren, M.
403 (2019). Fetal alcohol spectrum disorders from childhood to adulthood: a Swedish
404 population-based naturalistic cohort study of adoptees from Eastern Europe. *BMJ*
405 open, 9(10), e032407.

406 Lange, S., Probst, C., Gmel, G., Rehm, J., Burd, L. & Popova, S. 2017a. Global Prevalence of
407 Fetal Alcohol Spectrum Disorder Among Children and Youth A Systematic Review
408 and Meta-analysis. *JAMA Pediatr*, 171, 948-956.

409 Lange, S., Probst, C., Gmel, G., Rehm, J., Burd, L. & Popova, S. 2017b. Global Prevalence of
410 Fetal Alcohol Spectrum Disorder Among Children and Youth: A Systematic Review
411 and Meta-analysis. *JAMA Pediatr*, 171, 948-956.

412 May, P. A., Chambers, C. D., Kalberg, W. O., Zellner, J., Feldman, H., Buckley, D., Kopald, D.,
413 Hasken, J. M., Xu, R., Honerkamp-Smith, G., Taras, H., Manning, M. A., Robinson, L.
414 K., Adam, M. P., Abdul-Rahman, O., Vaux, K., Jewett, T., Elliott, A. J., Kable, J. A.,
415 Akshoomoff, N., Falk, D., Arroyo, J. A., Hereld, D., Riley, E. P., Charness, M. E., Coles,
416 C. D., Warren, K. R., Jones, K. L. & Hoyme, H. E. 2018. Prevalence of Fetal Alcohol
417 Spectrum Disorders in 4 US Communities. *JAMA*, 319, 474-482.

418 May, P. A., Fiorentino, D., Coriale, G., Kalberg, W. O., Hoyme, H. E., Aragon, A. S., Buckley,
419 D., Stellavato, C., Gossage, J. P., Robinson, L. K., Jones, K. L., Manning, M. & Ceccanti,
420 M. 2011. Prevalence of children with severe fetal alcohol spectrum disorders in
421 communities near Rome, Italy: new estimated rates are higher than previous
422 estimates. *Int. J. Environ. Res. Public. Health*, 8, 2331-51.

423 May, P. A. & Gossage, J. P. 2001. Estimating the prevalence of fetal alcohol syndrome - A
424 summary. *Alcohol Research & Health*, 25, 159-167.

425 Mcquire, C., Mukherjee, R., Hurt, L., Higgins, A., Greene, G., Farewell, D., Kemp, A. &
426 Paranjothy, S. 2019. Screening prevalence of fetal alcohol spectrum disorders in a
427 region of the United Kingdom: A population-based birth-cohort study. *Prev. Med.*,
428 118, 344-351.

429 Ministry of Housing Communities and Local Government 2019. The English Indices of
430 Deprivation. [https://www.gov.uk/government/statistics/english-indices-of-](https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019)
431 [deprivation-2019](https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019).

432 Morleo, M., Woolfall, K., Dedman, D., Mukherjee, R., Bellis, M. A. & Cook, P. A. 2011. Under-
433 reporting of foetal alcohol spectrum disorders: an analysis of hospital episode
434 statistics. *BMC Pediatr.*, 11.

435 Mukherjee, R., Layton, M., Yacoub, E. & Turk, J. 2011. Autism and autistic traits in people
436 exposed to heavy prenatal alcohol: data from a clinical series of 21 individuals and
437 nested case control study. *Advances in Mental Health and Intellectual Disabilities*.

438 Mukherjee, R., Wray, E., Curfs, L. & Hollins, S. 2015. Knowledge and opinions of professional
439 groups concerning FASD in the UK. *Adoption and Fostering*, 39, 212-224.

440 Okulicz-Kozaryn, K., Borkowska, M., & Brzózka, K. (2017). FASD prevalence among
441 schoolchildren in Poland. *Journal of Applied Research in Intellectual Disabilities*,
442 30(1), 61-70.

443 ONS 2020. Births in England and Wales: summary tables.

444 Popova, S., Lange, S., Probst, C., Gmel, G. & Rehm, J. 2017. Estimation of national, regional,
445 and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a
446 systematic review and meta-analysis. *Lancet Global Health*, 5, E290-E299.

447 Public Health England 2021. Public Health Profiles.

448 <https://fingertips.phe.org.uk/search/alcohol%20specific%20death>.

449 Raldiris, T. L., Bowers, T. G. & Towsey, C. 2018. Comparisons of intelligence and behavior in
450 children with fetal alcohol spectrum disorder and ADHD. *Journal of Attention*
451 *Disorders*, 22 (10), 959-970.

452 Rangmar, J., Hjern, A., Vinnerljung, B., Strömland, K., Aronson, M., & Fahlke, C. (2015).
453 Psychosocial outcomes of fetal alcohol syndrome in adulthood. *Pediatrics*, 135(1),
454 e52-e58.

455 Rasmussen, C., Tamana, S., Baugh, L., Andrew, G., Tough, S. & Zwaigenbaum, L. 2013.
456 Neuropsychological impairments on the NEPSY-II among children with FASD. *Child*
457 *Neuropsychology*, 19, 337-349.

458 Reynolds, R., McCarthy, R. & Cook, P. A. 2021. We do things differently here: the Greater
459 Manchester approach to preventing alcohol-exposed pregnancy. *Perspectives in*
460 *Public Health*. September 2021.

461 Roozen, S., Peters, G. J. Y., Kok, G., Townend, D., Nijhuis, J. & Curfs, L. 2016. Worldwide
462 Prevalence of Fetal Alcohol Spectrum Disorders: A Systematic Literature Review
463 Including Meta-Analysis. *Alcoholism-Clinical and Experimental Research*, 40, 18-32.

464 Sayal, K., Heron, J., Draper, E., Alati, R., Lewis, S. J., Fraser, R., ... & Gray, R. (2014). Prenatal
465 exposure to binge pattern of alcohol consumption: mental health and learning
466 outcomes at age 11. *European Child & Adolescent Psychiatry*, 23(10), 891-899.

467 Scholin, L., Mukherjee, R. a. S., Aiton, N., Blackburn, C., Brown, S., Flemming, K. M., Gard, P.
468 R., Howlett, H., Plant, M., Price, A. D., Shields, J., Smith, L. A., Suttie, M., Zammitt, D.
469 C., Cook, P. A. & Collaboration, U. F. R. 2021. Fetal alcohol spectrum disorders: an
470 overview of current evidence and activities in the UK. *Arch. Dis. Child*.

471 Smith, L., Savory, J., Couves, J. & Burns, E. 2014. Alcohol consumption during pregnancy:
472 Cross-sectional survey. *Midwifery*, 30, 1173-1178.

473 Streissguth, A. P., Bookstein, F. L., Barr, H. M., Sampson, P. D., O'malley, K. & Young, J. K.
474 2004. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal
475 alcohol effects. *J. Dev. Behav. Pediatr.*, 25, 228-38.

476 World Health Organisation 2012. WHO Global Prevalence Study on FASD. WHO Research
477 Initiative on Alcohol, Health and Development, WHO International Collaborative
478 Research Project on Fetal Alcohol Spectrum Disorders (FASD).

479 Young, S., Absoud, M., Blackburn, C., Branney, P., Colley, B., Farrag, E., Fleisher, S., Gregory,
480 G., Gudjonsson, G. H., Kim, K., O'malley, K. D., Plant, M., Rodriguez, A., Ozer, S.,
481 Takon, I., Woodhouse, E. & Mukherjee, R. 2016. Guidelines for identification and
482 treatment of individuals with attention deficit/hyperactivity disorder and associated
483 fetal alcohol spectrum disorders based upon expert consensus. *BMC Psychiatry*, 16,
484 324.

485

Figure legends

Figure 1. Study design

Figure 2. Flow of participants through the study.

SFA: small for age; SEN: on school educational needs register; LAC: 'looked after child' i.e. in the care of the local authority; PreVLAC: previously looked after, i.e. adopted.

Table 1

Table 1: Measures used and Fetal Alcohol Spectrum Disorder (FASD) domains of impairment

Domain	Sub-domain	Measure
Growth		Height below 9 th percentile and Weight below 9 th percentile, medical history
Face		Photographic measurements 4 digit FAS Facial Measurement software.
Central Nervous System	Brain	OFC below 2 nd centile, medical history or brain scan report
	Hard/ Soft Neurological signs	SSP Defined differences in 2 or more domains History of formally diagnosed motor disorder e.g. dyspraxia History of epilepsy or other neurological issues (from medical history)
	Communication	CCC-2, Vineland communication domain. Defined by abnormality >1.5 standard deviations below the mean
	Cognition	WISC V: Full Scale IQ 2 standard deviations from norm or 2 standard deviations between different subdomains
	Executive Function	BRIEF overall score: Score above clinical cut off range NEPSY executive function domain Score 1.5 standard deviations from norm or 2 standard deviations between subdomains
	Memory	WISC V, NEPSY Memory domain
	Attention	SDQ attention domain scores above clinical cut offs

		NEPSY attention domain
	Adaptive behaviour, social skills	SCQ (score above 15), SDQ (score above clinical cut off), Vineland Social domain, Vineland Daily Living Skills domain (both scores 1.5 standard deviations from mean)
	Academic	Teacher report, below average level, has EHC Plan
Alcohol consumption of birth mother		History information sheet

497

498 BRIEF: Behaviour Rating Inventory of Executive Function

499 CCC-2: Communication Checklist for Children

500 EHC Plan: Education Health and Care Plan

501 FAS: Fetal Alcohol Syndrome

502 IQ: Intelligence Quota

503 NEPSY: NEuroPSYchological Assessment

504 OFC: Occipitofrontal Circumference

505 SSP: Short Sensory Profile

506 SCQ: Social Communication Questionnaire

507 SDQ: Strengths and Difficulties Questionnaire

508 WISC-V: Wechsler Intelligence Scale for Children Fifth UK Edition

509

Table 2

Table 2: Screening and assessment data by school

	School1 (baseline N=44)	School2 (baseline N=118)	School3 (baseline N=59)	Total (N=220)
Screened at stage one n (% of baseline)	38 (86)	109 (92)	56 (95)	203 (92)
Sex , n(% of baseline)				
Male	18 (40)	55 (46)	30 (51)	103 (47)
Female	20 (45)	54 (46)	26 (44)	100 (45)
Age , Years (y) & months (m)				
Median	8y11m	8y10m	8y6m	8y10m
[Interquartile range]	[8y9m, 9y5m]	[8y5m, 9y6m]	[8y3m, 8y11m]	[8y 5m, 9y4m]
(range)	(8y3m, 9y9m)	(8y0m, 9y10m)	(8y0m, 9y8y)	(8y0m, 9y10m)
Physical screen positive n (% of baseline)				
Height <9 th percentile	4 (9)	7 (6)	2 (3)	13 (6)
Weight <9 th percentile	2 (5)	3 (3)	2 (3)	7 (3)
OFC <2th percentile	1 (2)	1(1)	1 (2)	3 (1)
Reason for recruitment n (% of invited)				
SEN	14(66)	7 (43)	5 (50)	26 (13)
SFA	3(14)	5 (31)	4 (40)	12 (6)
LAC	2(10)	3 (18)	1 (10)	6 (3)
SFA+SEN	2(10)	0	0	2 (1)
SFA + prevLAC	0	1 (6)	0	1 (0.5)
Parent opt-in	0	3 (16)	0	3 (1)
Invited to second phase	21	19	10	50
Phase two assessments	N=10	N=9	N=7	N=26
Referral reason (% of phase two participants)				
SEN	5 (50)	3 (33)	4 (57)	12 (46)
SFA	3 (30)	0	2 (29)	5 (19)
LAC	0	2 (22)	1 (14)	3 (12)
SFA and SEN	2 (20)	0	0	2 (8)
SFA and PrevLAC	0	1 (11)	0	1 (4)
parent opt in	0	3 (33)	0	3 (11)
Maternal Ethnicity , n(%)				

White UK	10 (100)	8 (89)	6 (86)	24 (92)
Non white	0	1 (11)	0	1 (4)
Not reported	0	0	1 (14)	1 (4)
Maternal educational qualifications, highest received n(%)				
<4 GCSEs	2 (20)		1 (14)	3 (12)
4+GCSEs	4 (40)		2 (29)	6 (23)
2+A levels	2 (20)	3 (33)	1 (14)	6 (23)
Degree	2 (20)	4 (44)	2 (29)	8 (30)
Missing data	0	2 (22)	1 (14)	3 (12)
Full assessment				
Deficits in three subdomains met, n(% of assessed)	8 (80)	7 (78)	6 (86)	21 (80)
FASD, n (% of assessed)				
FASD	1 (10)	3 (33)	0 (0)	4 (15)
FASD and possible FASD	3 (30)	4 (44)	1 (10)	8 (30)
Other outcomes				
ASD	0 (0)	2 (22)	3 (43)	5 (19)
ADHD	2 (20)	0 (0)	1 (14)	3 (12)
DLD	2 (20)	1 (10)	0 (0)	3 (12)
General learning disability	0 (0)	0 (0)	2 (28)	2 (8)
No disorder	3 (30)	2 (20)	0 (0)	5 (19)
FASD prevalence per 100 [95% CI]				
FASD	2.3 [0.3,14.8]	2.5 [0.8, 7.4]	No observations	1.8 [1.0,3.4]
FASD and possible FASD	7.0 [2.2,19.8]	3.4 [1.3, 8.7]	1.7 [0.2,11.1]	3.6 [2.1,6.3]

512 SEN: on school educational needs register; SFA: small for age; LAC: 'looked after child', i.e.

513 under care of local authority; PrevLAC: previously looked after child, i.e. adopted; OFC:

514 occipital frontal circumference; GCSE: General Certificate of Education, qualification usually

515 taken at age 16 years; A level: Advanced Level, qualification usually taken at age 18 years;

516 FASD: fetal alcohol spectrum disorder; ASD: autism spectrum disorder; ADHD: attention

517 deficit hyperactivity disorder; DLD: developmental language disorder.

518

Table 3

Table 3: prenatal exposure data from cases with a complete dataset

Reported Prenatal exposures	FASD N=4	Possible FASD n=4	Other N= 18	TOTAL N=26
Anticonvulsants	0	0	0	0
Illegal drugs	1(25%)	0	1 (6%)	2 (8%)
Alcohol				
Significant risk ^a	3 (75%)	3(75%)	4 (22%)	10 (38%)
Low risk ^b	0	1 (25%)	7 (40%)	8 (30%)
No alcohol reported	1(25%)	0	7 (40%)	8 (30%)

^aCut off for significant risk defined as four or more alcoholic drinks on four or more

occasions or greater than seven units a week throughout the term of the pregnancy

^b Low risk: alcohol consumed, but not meeting threshold above (Kelly, et al., 2009; Sayal et al., 2013).

Table legends

Table 2: Measures used and Fetal Alcohol Spectrum Disorder (FASD) domains of impairment

BRIEF: Behaviour Rating Inventory of Executive Function

CCC-2: Communication Checklist for Children

EHC Plan: Education Health and Care Plan

NEPSY: NEuroPSYchological Assessment

OFC: Occipitofrontal Circumference

SSP: Short Sensory Profile

SCQ: Social Communication Questionnaire

SDQ: Strengths and Difficulties Questionnaire

WISC-V: Wechsler Intelligence Scale for Children Fifth UK Edition

Table 2: Screening and assessment data by school

SEN: on school educational needs register; SFA: small for age; LAC: 'looked after child', i.e.

under care of local authority; PrevLAC: previously looked after child, i.e. adopted; OFC:

occipital frontal circumference; GCSE: General Certificate of Education, qualification usually

taken at age 16 years; A level: Advanced Level, qualification usually taken at age 18 years;

FASD: fetal alcohol spectrum disorder; ASD: autism spectrum disorder; ADHD: attention

deficit hyperactivity disorder; DLD: developmental language disorder.

549 Table 3: prenatal exposure data from cases with a complete dataset

550 ^aCut off for significant risk defined as four or more alcoholic drinks on four or more

551 occasions or greater than seven units a week throughout the term of the pregnancy.

552 ^bLow risk: alcohol consumed, but less than four or more occasions or less than seven units a

553 week

Figure 1




Figure 2

